DOC1021 Cell-based Immunotherapy in Combination With Standard Chemoradiation for Adjuvant Therapy of Glioblastoma: Early Results From an Expanded Access Protocol of a Phase I Trial (P11-6.010) | Synapse
June 13, 2026
DOC1021 Cell-based Immunotherapy in Combination With Standard Chemoradiation for Adjuvant Therapy of Glioblastoma: Early Results From an Expanded Access Protocol of a Phase I Trial (P11-6.010)
Key Points
The study aims to report the results of an expanded access protocol for DOC1021 in glioblastoma patients.
Expanded access protocol evaluating DOC1021.
Included adult patients with new or recurrent glioblastoma.
Observational components of a phase I trial.
Initial results indicate promising responses in some patients receiving DOC1021.
Early data suggest potential safety and efficacy when combined with standard chemoradiation.
Abstract
To report ongoing results of an expanded access protocol evaluating DOC1021 in adult patients with new or recurrent glioblastoma.